Please assess the completion status of the following clinical trial:

Trial Title: Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult subjects who wish to participate after signing the informed consent.~2. Aged between 18 and 65 years.~3. HP infection diagnosed by endoscopic gastric biopsy.~4. Subjects who fulfill the following HP eradication criteria according to Maastricht 3 Consensus Report:~   * Non ulcer dyspepsia with gastric biopsy positive for HP infection,~  * Uncomplicated duodenal ulcer (without active bleeding, perforation or stenosis) with gastric biopsy positive for HP infection,~  * Uncomplicated benign gastric ulcer (without active bleeding, perforation or stenosis) with gastric biopsy positive for HP infection,~  * Chronic intake of NSAIDs with gastric biopsy positive for HP infection without active gastrointestinal bleeding.~Exclusion Criteria:~1. Pregnant or lactating women.~2. Subjects who have previously received the PLA or CLA treatment.~3. Subjects who are diagnosed by endoscopy with upper gastrointestinal bleeding secondary to active peptic ulcer (gastric or duodenal) with injuries classified in any of the following stages of the Forrest Classification: I-a (Spurting hemorrhage), I-b (Oozing hemorrhage), II-a (Visible vessel) or II-b (Adherent clot).~4. Subjects who are diagnosed by endoscopy with upper gastrointestinal bleeding by erosive gastritis secondary to active NSAID with positive biopsy for HP infection and whose clinical conditions require hospitalization and / or blood transfusion.~5. Subjects with psychiatric disorders including eating disorders.~6. Subjects with chronic degenerative diseases including uncontrolled hepatic, renal or endocrine diseases (except diabetes controlled by oral hypoglycemic agents or controlled hypothyroidism), malabsorption or chronic diarrhea, history of seizures or epilepsy, gastric surgery or subjects with oncological diseases.~7. Subjects with previous allergic reactions to any of the treatment components: Pantoprazole, Amoxicillin, Clarithromycin, Azithromycin or Levofloxacin.~8. Subjects with a history of photosensitivity or tendinitis secondary to quinolones intake.~9. Subjects who are taking any of the following medications:~   * NSAIDS: Fenbufen~  * ergot~  * Oral anticoagulants~  * Cyclosporine~  * Digoxin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CLA (Clarithro+Lanso+Amoxi) (Type: ACTIVE_COMPARATOR): Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
- PLA (Panto+Levoflox+Azithro) (Type: EXPERIMENTAL): Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).